KL earnings call for the period ending December 31, 2020.
Inspur AI Server Wins "Server Solution of the Year" Award in 2021 Data Breakthrough Awards Program
The Labour Party leader was told to leave a pub in Bath by an irate landlord.
Foxconn Technology Group, the world's largest electronics manufacturer, has reached a new deal with reduced tax breaks for its scaled back project in southeast Wisconsin, Gov. Tony Evers and the the company announced on Monday. Details of the new deal were not immediately released. It was scheduled to be approved at a Tuesday meeting of the Wisconsin Economic Development Corp., the state's top jobs agency that previously negotiated the initial deal with Foxconn.
Amazon (NASDAQ: AMZN) has been a big winner for investors. This growing customer base is helping Amazon cement its lead by attracting lots of third-party merchants. In the fourth quarter, sales of third-party units made up 55% of Amazon's total paid units in its retail business -- the highest level in the company's history.
Fifth Third Bank names Jay Plum head of Mortgage
How much will the healthcare giant suffer, and what does this mean for worldwide vaccination efforts?
Zepp Health Corp. (NYSE: ZEPP) today announced that it has chosen to move the vast majority of its IT infrastructure to Amazon Web Services, Inc. (AWS), an Amazon.com company. Zepp Health is leveraging AWS’s global infrastructure, industry-leading security and compliance capabilities, and comprehensive suite of cloud services to drive its business strategy in more than 70 countries and support 38 million smart wearable device users worldwide. Zepp Health developed a proprietary technology platform, which has driven an expanding line of smart health devices for consumers, data analytics services for population health, and industrial medical technology for diagnostics and care delivery. The company is one of the largest global developers of smart wearable health and consumer fitness devices, shipping 46 million units in 2020.
ST. LOUIS, April 19, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 first quarter on Monday, May 10, 2021 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments. What: Stereotaxis first quarter 2021 financial results conference call When: Monday, May 10, 2021 at 10:00 a.m. EST (7:00 a.m. PST) Dial In Number: To access the live call, dial 800-367-2403 (US and Canada) or 334-777-6978 (International) and give the participant pass code 6657929. Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/ Call Replay: A phone replay of the call will be available for one month beginning approximately two hours following the end of the call through June 10, 2021. To request access for a replay of the conference call, please Click Here. About Stereotaxis Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com. Company Contacts:David L. FischelChairman and Chief Executive Officer Kimberly PeeryChief Financial Officer firstname.lastname@example.org
CARLSBAD, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2021 financial results on May 6, 2021, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast Participants To access the live webcast, please visit the Investor Relations Section of ATEC’s Corporate Website at investors.alphatecspine.com. Participants should go to the website at least 15 minutes before the event to register, and download and install any necessary software. Dial-in Participants Registration may be completed by visiting the following registration link prior to, or on the day of, the webcast: http://www.directeventreg.com/registration/event/9350774. Once registered, each dial-in participant will be provided access details and a registrant ID. Email reminders will also be sent to registered participants. Replay Participants A replay of the webcast will remain available through the Investor Relations section of ATEC’s Corporate Website at investors.alphatecspine.com for twelve months. In addition, a replay of the audiocast will be available beginning two hours after the call’s completion until May 13, 2021. The replay dial-in numbers are (800)585-8367 for domestic callers and (416)621-4642 for international callers. Please use the replay conference ID number 9350774. About Alphatec Holdings, Inc. Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the SafeOp Neural InformatiX System to safely and reproducibly treat spine’s various pathologies and achieve the goals of spine surgery. Alphatec’s ultimate vision is to be the Standard Bearer in Spine. For more information, visit us at www.atecspine.com. Investor/Media Contact:Tina Jacobsen, CFAInvestor Relations(760) email@example.com Company Contact:J. Todd KoningChief Financial OfficerAlphatec Holdings, Inc.firstname.lastname@example.org
Presentations will highlight new data on the safety, efficacy, and tolerability of once-daily, topical roflumilast cream for the treatment of chronic, mild-to-severe plaque psoriasis as well as once-daily, topical roflumilast foam for the treatment of scalp and body psoriasis and seborrheic dermatitis.WESTLAKE VILLAGE, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will present new data from three studies evaluating the safety, efficacy, and tolerability of its once-daily, topical roflumilast cream and foam at the American Academy of Dermatology Virtual Meeting Experience (VMX) April 23 - 25, 2021. “Patients suffering from plaque psoriasis, scalp psoriasis, and seborrheic dermatitis have significant unmet needs given the lack of efficacious, safe, tolerable topical options for long-term use,” said Patrick Burnett, M.D., Ph.D., FAAD, Chief Medical Officer, Arcutis. “We are pleased to share these new data that further reinforce the potential of roflumilast cream and foam in various inflammatory skin diseases. If approved by the FDA, our therapies could change the treatment paradigm for patients and their providers in addressing challenging inflammatory dermatological conditions that can significantly impact quality of life.” The data include positive results from a Phase 2b study of roflumilast foam for the treatment of scalp and body psoriasis, as well as a Phase 2 study of roflumilast foam in patients with seborrheic dermatitis. Two additional poster slide presentations will feature sub-analyses from the previously published Phase 2b study of roflumilast cream in the treatment of chronic, mild-to-severe plaque psoriasis: 1) the correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes, and 2) the treatment of steroid-sensitive areas of the body including the face, neck, and intertriginous areas. Finally, Dr. Kim Papp will present results from a new measurement, PASI-HD, which he developed in conjunction with the Arcutis medical team and which was used in the Phase 2b study of roflumilast cream in plaque psoriasis. In areas where the affected body surface area is low (<10%), PASI-HD better distinguishes disease severity than the traditional Psoriasis Area and Severity Index (PASI), which is a gold standard measure in psoriasis clinical trials. Details of Arcutis’ AAD Virtual Congress presentations include: Late-breaking Oral Presentation (PSO 204): Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-blind, Vehicle-controlled Phase 2b StudyDate: April 24, 2021Poster Presentation Plus Recording (SebDerm 203): Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Randomized, Double-blind, Vehicle-controlled Phase 2 Study Date: April 23, 2021Poster Presentation (PSO 201): Correlation of Itch Response to Roflumilast Cream with Disease Severity and Patient-Reported Outcomes in Patients with Chronic Plaque Psoriasis Date: April 23, 2021Poster Presentation (PSO 201): Roflumilast Cream Significantly Improves Chronic Plaque Psoriasis in Patients with Steroid-Sensitive Area InvolvementDate: April 23, 2021Poster Presentation (PSO 201): The PASI-HD Improved Precision in Measuring Disease Severity in Subjects with Mild-to-Moderate Plaque Psoriasis Treated with Roflumilast Cream, a Phosphodiesterase-4 InhibitorDate: April 23, 2021 Roflumilast is a highly potent phosphodiesterase-4 (PDE4) inhibitor in development for plaque psoriasis (PsO). Arcutis is investigating roflumilast as a once-daily, nonsteroidal, topical treatment for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter. Join the conversation with the hashtag #AADVMX2021. About PsoriasisPsoriasis is a common, non-contagious, immune-mediated skin disease that affects approximately 8.6 million patients in the United States. About 90% of patients develop plaque psoriasis, which is characterized by raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and are often itchy and sometimes painful. Scalp psoriasis is a manifestation of plaque psoriasis characterized by plaques in the hair-bearing area of the scalp and sometimes extending to the forehead, back of the neck, or behind or inside the ears. Patients with scalp psoriasis commonly have plaques on other areas of the body as well. Scalp psoriasis is present in nearly half of Americans with psoriasis. As with psoriatic plaques on other parts of the body, scalp psoriasis is often itchy and sometimes painful. It can also be associated with hair loss. About Seborrheic DermatitisSeborrheic dermatitis affects more than 10 million people in the United States, and is a common, chronic, or recurrent inflammatory skin disease that causes red patches covered with large, greasy, flaking yellow-gray scales, and persistent itch. Seborrheic dermatitis occurs most often on the scalp, face (especially on the nose, eyebrows, ears, and eyelids), upper chest, and back. About Topical Roflumilast Cream and FoamRoflumilast Cream and Foam are once-daily, topical formulations of a highly potent and selective PDE4 inhibitor (roflumilast). The foam formulation was developed to treat inflammatory dermatoses in hair-bearing areas of the body, such as the scalp, although it is usable in all areas of the body. Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for oral treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. Roflumilast has shown greater potency (25- to 300-fold) than the two other FDA-approved PDE4 inhibitors for dermatology. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, atopic dermatitis, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis and the systemic treatment of plaque psoriasis. About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter. Forward Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding the potential for roflumilast to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Investor and Media Contact:Heather Rowe Armstrongharmstrong@arcutis.com805-418-5006 ext. 740
Vancouver, British Columbia--(Newsfile Corp. - April 19, 2021) - Lynx Global Digital Finance Corporation (CSE: LYNX) ("LYNX" or the "Company"), formerly CannaOne Technologies Inc. (CSE: CNNA) (OTC Pink: CNONF) (FSE: 3CT), is pleased to announce that it has signed a definitive share purchase agreement (the "Agreement") in connection with its previously disclosed (see March 16, 2021 news release) acquisition (the "Acquisition") of a 51% equity interest of Philippines-based Direct Agent 5 Inc. ("DA5").DA5 serves ...
Logz.io today announced it has been named a Leader and Fast Mover in the GigaOm Radar Report for Cloud Observability, 2021*.
X-Ray Tube Market Research Report by Type (Microfocus X-Ray Tubes and Rotating Anode Tube), by Product (Bipolar and Unipolar), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, April 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "X-Ray Tube Market Research Report by Type, by Product, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06063093/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global X-Ray Tube Market is expected to grow from USD 3,046.72 Million in 2020 to USD 5,169.84 Million by the end of 2025.2. The Global X-Ray Tube Market is expected to grow from EUR 2,671.42 Million in 2020 to EUR 4,533.01 Million by the end of 2025.3. The Global X-Ray Tube Market is expected to grow from GBP 2,374.90 Million in 2020 to GBP 4,029.86 Million by the end of 2025.4. The Global X-Ray Tube Market is expected to grow from JPY 325,163.08 Million in 2020 to JPY 551,753.18 Million by the end of 2025.5. The Global X-Ray Tube Market is expected to grow from AUD 4,424.25 Million in 2020 to AUD 7,507.29 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the X-Ray Tube to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Type, the X-Ray Tube Market studied across Microfocus X-Ray Tubes and Rotating Anode Tube. Based on Product, the X-Ray Tube Market studied across Bipolar and Unipolar. Based on Application, the X-Ray Tube Market studied across Aerospace & Defense, Food & Beverage, Industrial Equipment, and Medical & Pharmaceuticals. "The Asia-Pacific is projected to witness the highest growth during the forecast period"Based on Geography, the X-Ray Tube Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded the largest size in the X-Ray Tube Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global X-Ray Tube Market including Acme Metal Spinning, Inc., Airport Luggage Scanners,, Altair Technologies, Inc., Brand X-ray Tube Co. Inc., Canon Electron Tubes & Devices Co. Ltd, Comet Holding AG, CoorsTek, Inc., Dunlee, General Electric Co., Gulmay, H.C. Starck, Inc., Hitachi Ltd, Kodex, Inc., Koninklijke Philips NV, Lafco India Scientific Industries, LND, Inc., Lohmann X-Ray, Malvern Panalytical Ltd, Micro X-Ray, Moxtek, Inc., National X-Ray Corp., Newco, Inc., Osram Sylvania, Oxford Instruments PLC, Panalytical Inc., PANalytical, Inc., PEG, Inc. (Precision Electronic Glass), Penta Laboratories, PHIDER Electronics Co., Ltd., Rad Source TSG, Shimadzu Corporation, Siemens AG, Teshima Technology, Thermo Kevex X-Ray Inc., Toshiba Electron Tubes & Devices Co Ltd, Varex Imaging Corporation, Willick Engineering, X-ray crystallography, Xiamen Innovacera Advanced Materials Co., Ltd, and Yxlon International. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the X-Ray Tube Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global X-Ray Tube Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global X-Ray Tube Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global X-Ray Tube Market?4. What is the competitive strategic window for opportunities in the Global X-Ray Tube Market?5. What are the technology trends and regulatory frameworks in the Global X-Ray Tube Market?6. What are the modes and strategic moves considered suitable for entering the Global X-Ray Tube Market?Read the full report: https://www.reportlinker.com/p06063093/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 19, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the journal EuroIntervention has published an article entitled, "Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina." The article, authored by Carlo Zivelonghi, M.D., Antwerp Cardiovascular Center, Antwerp, Belgium, describes objective improvements in effort tolerance and oxygen kinetics as assessed ...
COVID-19 has driven many U.S. enterprises to invest in cloud-based Microsoft products and services and seek provider support, ISG (Nasdaq: III) finds.
We hereby inform you about the decisions adopted at the Extraordinary General Meeting of Shareholders of Medicinos Bankas UAB (office address: Pamėnkalnio 40, Vilnius, company registration number 112027077, VAT number LT120270716) which was held on 19 April 2021 (please see the attached documents). More information: Aleksejus Tonkich, Member of the Board, Director of the Financial Service, Deputy Head of Administration Phone: + 370 698 34055, email: firstname.lastname@example.org Attachments Annex 1 Contract on the Activities of a Member of the Supervisory Board 2021-04-16 Decisions of General Meeting of Shareholders
SilverBow Resources, Inc. (NYSE: SBOW) ("SilverBow" or "the Company") today provided an operational and financial update including the successful extension of its senior secured revolving credit facility (the "Credit Facility").
FORM 8.3 IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAon plcClass of relevant security to which the dealings being disclosed relate (Note 2)US$0.01 ordinary sharesDate of dealing16th April 2021 2. INTERESTS AND SHORT POSITIONS (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) LongShort Number(%)Number(%)(1) Relevant securities9,414,581 4.16634% (2) Derivatives (other than options)N/A (3) Options and agreements to purchase/sellN/A Total9,414,581 4.16634% (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security:LongShort Number(%)Number(%)(1) Relevant securitiesN/A (2) Derivatives (other than options)N/A (3) Options and agreements to purchase/sellN/A TotalN/A 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/saleNumber of relevant securitiesPrice per unit (Note 5)Purchase7,599239.12Purchase800239.12Purchase700239.12Purchase600239.12Purchase73239.12Purchase203239.12Purchase14,364239.12Purchase2,828239.12Purchase6,060239.12Purchase5,959239.12Purchase4,747239.12Purchase65239.12Purchase222239.12Purchase37239.12Purchase74239.12Purchase178,858239.12Sale700239.12Sale46239.12Sale5,852239.12Sale2,394239.12Sale798239.12Sale1,212239.12Sale38239.12Sale57239.12Sale26239.12Sale30239.12Sale326239.12Sale56239.12Sale600239.12Sale800239.12 (b) Derivatives transactions (other than options transactions) Product name, e.g. CFDNature of transaction (Note 6)Number of relevant securities (Note 7)Price per unit (Note 5)N/A (c) Options transactions in respect of existing relevant securities (i) Writing, selling, purchasing or varying Product name, e.g. call optionWriting, selling, purchasing varying etc.Number of securities to which the option relates (Note 7)Exercise priceType, e.g. American, European etc.Expiry dateOption money paid/received per unit (Note 5)N/A (ii) Exercising Product name, e.g. call optionNumber of securitiesExercise price per unit (Note 5)N/A (d) Other dealings (including transactions in respect of new securities) (Note 4) Nature of transaction (Note 8)DetailsPrice per unit (if applicable) (Note 5)N/A 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.N/A Is a Supplemental Form 8 attached? (Note 9)NO Date of disclosure19th April 2021 Contact nameLionel ColacoTelephone number 020 33956098If a connected EFM, name of offeree/offeror with which connectedN/AIf a connected EFM, state nature of connection (Note 10)N/A
The Ingenuity drone completes the first powered, controlled flight by an aircraft on another world.
Danske Bank's chief executive Chris Vogelzang, who was hired to help it recover from a multi-billion dollar money laundering scandal, resigned on Monday after Dutch authorities labelled him as a suspect in a separate case at ABN Amro. Vogelzang said he was quitting after the Dutch prosecution service said it was investigating three former board members at ABN. The Dutch bank also said it had reached a 480 million euro ($577 million) settlement over systematic failures to tackle money laundering.